A rehash of my post on 27/9/2017
As of yesterday's closing, Market Cap of RAP was $56m whereas we were at $19.8m.
Both are in the FDA process, one with a fantastic preliminary result and one needs to redo the trial due to certain procedural issues.
I would prefer to think that we are very undervalued compared to our peers.
Some here raise the possibility of a CR, I would hope the CR would be done at least at the MC of $50m or higher than our current $20m.
NTI Chart, page-357
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
